WO2012115177A1 - Dérivé de n-[(biaryloxy)alkylcarbonyle]sulfonamide - Google Patents

Dérivé de n-[(biaryloxy)alkylcarbonyle]sulfonamide Download PDF

Info

Publication number
WO2012115177A1
WO2012115177A1 PCT/JP2012/054350 JP2012054350W WO2012115177A1 WO 2012115177 A1 WO2012115177 A1 WO 2012115177A1 JP 2012054350 W JP2012054350 W JP 2012054350W WO 2012115177 A1 WO2012115177 A1 WO 2012115177A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
acceptable salt
atom
pharmacologically acceptable
Prior art date
Application number
PCT/JP2012/054350
Other languages
English (en)
Japanese (ja)
Inventor
達矢 西
健 有田
Original Assignee
第一三共株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 第一三共株式会社 filed Critical 第一三共株式会社
Publication of WO2012115177A1 publication Critical patent/WO2012115177A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

La présente invention concerne un composé qui possède un excellent effet anti-agrégation plaquettaire et qui est utile dans la prophylaxie et/ou le traitement de maladies thromboemboliques. Ledit composé est représenté par la formule générale (I) ou son sel pharmacologiquement acceptable. (Dans ladite formule générale (I), n représente 1 ou 2 ; R1 représente un atome d'halogène, un groupe cyano, un groupe amine, un groupe alkyle en C1-4, un groupe alkyle en C1-4 halogéné ou un groupe alkoxy en C1-4 ; R2 représente un atome d'hydrogène, un atome d'halogène, un groupe cyano ou un groupe alkyle en C1-4 ; R3 et R4 représentent chacun un atome d'hydrogène, un groupe alkyle en C1-4, un groupe alkyle en C1-4 halogéné, un groupe alkoxy en C1-4 alkyle en C1-4 ou un groupe qui forme un groupe cycloalkyle en C3-5 ; R5 représente un atome d'hydrogène, un atome d'halogène, un groupe hydroxyle, un groupe nitro, un groupe alkyle en C1-4 ou un groupe amine ; R6 représente un atome d'hydrogène, un atome d'halogène ou un groupe alkyle en C1-4 ; R7 et R8 représentent chacun un atome d'hydrogène, un atome d'halogène ou un groupe alkyle en C1-4 ; R9 et R10 représentent chacun un atome d'hydrogène ou un groupe alkyle en C1-4 ; R11 représente un groupe alkyle en C1-4 ou un groupe phényle ; X représente un atome d'oxygène, un atome de soufre ou -CH2- ; Y représente un atome d'azote ou =C(Ra)- ; Ra représente un atome d'hydrogène, un atome d'halogène ou un groupe alkyle en C1-4 ; et Z représente un atome d'azote ou =CH-.)
PCT/JP2012/054350 2011-02-25 2012-02-23 Dérivé de n-[(biaryloxy)alkylcarbonyle]sulfonamide WO2012115177A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011039580 2011-02-25
JP2011-039580 2011-02-25

Publications (1)

Publication Number Publication Date
WO2012115177A1 true WO2012115177A1 (fr) 2012-08-30

Family

ID=46720951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/054350 WO2012115177A1 (fr) 2011-02-25 2012-02-23 Dérivé de n-[(biaryloxy)alkylcarbonyle]sulfonamide

Country Status (1)

Country Link
WO (1) WO2012115177A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03173870A (ja) * 1989-02-10 1991-07-29 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
JPH04334351A (ja) * 1991-01-24 1992-11-20 Dr Karl Thomae Gmbh ビフェニル誘導体、これらの化合物を含む製薬組成物及びそれらの調製法
US5356904A (en) * 1992-10-07 1994-10-18 Merck & Co., Inc. Carbostyril oxytocin receptor antagonists
JPH09500134A (ja) * 1993-07-16 1997-01-07 メルク エンド カンパニー インコーポレーテッド ベンゾオキサジノンおよびベンゾピリミジノンピペリジニル早産防止オキシトシン受容体拮抗剤
WO2003022214A2 (fr) * 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Composes a base de piperazine et d'homopiperazine
WO2011024933A1 (fr) * 2009-08-28 2011-03-03 第一三共株式会社 Dérivé d'acide 3-(biaryloxy)propionique

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03173870A (ja) * 1989-02-10 1991-07-29 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
JPH04334351A (ja) * 1991-01-24 1992-11-20 Dr Karl Thomae Gmbh ビフェニル誘導体、これらの化合物を含む製薬組成物及びそれらの調製法
US5356904A (en) * 1992-10-07 1994-10-18 Merck & Co., Inc. Carbostyril oxytocin receptor antagonists
JPH09500134A (ja) * 1993-07-16 1997-01-07 メルク エンド カンパニー インコーポレーテッド ベンゾオキサジノンおよびベンゾピリミジノンピペリジニル早産防止オキシトシン受容体拮抗剤
WO2003022214A2 (fr) * 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Composes a base de piperazine et d'homopiperazine
WO2011024933A1 (fr) * 2009-08-28 2011-03-03 第一三共株式会社 Dérivé d'acide 3-(biaryloxy)propionique

Similar Documents

Publication Publication Date Title
TWI817870B (zh) Ｇｌｐ-１受體激動劑及其用途
TW202204323A (zh) 經取代之嗒𠯤化合物
EP2827857A1 (fr) Dihydro-thiazine spirocycliques et inhibiteurs de bace dihydro-oxazine et compositions et utilisations de ceux-ci
WO2006051826A1 (fr) Composé hétérocyclique azoté et utilisation pharmaceutique de celui-ci
EP2343296A1 (fr) Procédé pour la purification de la palipéridone
JP6615896B2 (ja) アルドステロン合成酵素阻害剤
AU2019326647A1 (en) (1,2,4)triazolo(1,5-a)pyridine compound as JAK inhibitor and application thereof
JPH0747585B2 (ja) イソオキサゾール誘導体
KR20160142402A (ko) 도파민 d1 리간드로서 헤테로방향족 화합물 및 이의 용도
JPH10504820A (ja) Ｎ−置換されたフェノチアジン類の使用
JP2876712B2 (ja) 光学活性ピラノベンゾオキサジアゾール誘導体
WO1999054303A1 (fr) Derives tetrahydrobenzindoles actifs au plan optique
JP5597202B2 (ja) ３−（ビアリールオキシ）プロピオン酸誘導体
WO2009075504A2 (fr) Forme cristalline du p-toluènesulfonate de bépostatine, son procédé de préparation et composition pharmaceutique la contenant
US11299462B2 (en) Crystal form of oxopicolinamide derivative and preparation method therefor
CA2707095A1 (fr) Derives phenyle-oxetanyle
JP2021525784A (ja) チエノ［２，３−ｃ］ピリダジン−４（１Ｈ）−オン系誘導体及びその使用
WO2012115177A1 (fr) Dérivé de n-[(biaryloxy)alkylcarbonyle]sulfonamide
JP5606440B2 (ja) チアベンゾアズレンプロピオン酸誘導体の製造法
EP3634409B1 (fr) Antagonistes des récepteurs de l'orexine
JP5983714B2 (ja) 含フッ素アミノ酸プロドラッグの結晶形とその製造方法
WO2012115176A1 (fr) Dérivé d'acide 3-(biaryloxy) propionique
JP2010047517A (ja) 神経栄養因子の活性が関与する疾患の治療または予防剤、およびその製造方法
WO2018206959A1 (fr) Antagonistes des récepteurs de l'orexine
CN116535424A (zh) 作为malt1抑制剂的三并环化合物及其药物组合物和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12749413

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12749413

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP